14 active shortage notices across 5 countries · 1 anticipated.
Last updated 1 Nov 2026 · sourced from official medicines regulators
| 31 Aug 2026 |
| AIFA |
| Canada | medium | 3 | 22 Oct 2024 | 8 May 2026 | HC |
| Belgium | medium | 1 | 9 Feb 2026 | 18 May 2026 | FAMHP |
| Spain | medium | 1 | 30 Oct 2025 | 14 May 2026 | AEMPS |
Yes. As of the latest regulator updates, Dabigatran-Etexilate-Mesilate has 14 active shortage notices across 5 countries (Australia, Italy, Canada, Belgium, Spain). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Dabigatran-Etexilate-Mesilate shortages to causes not stated by the regulator, manufacturing problems, supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 8 May 2026 to 1 Feb 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Acenocoumarol · Heparin (Heparin Sodium In 0.9% Sodium Chloride Injection) · Heparin Sodium Injection Usp · Heparin Sodium · Heparin-Sodium · Heparin Sodium Inj. Usp
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.